Emtricitabin (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Emtricitabin" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

4^th place

8^th place

2^nd place

5^th place

2web.archive.org

1^st place

2^nd place

low place

43^rd place

3,257^th place

1,590^th place

1,293^rd place

373^rd place

low place

low place

ama-assn.org

archinte.ama-assn.org

Lim SG; Ng TM; Kung N; in sod. (2006). »A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B«. Arch. Intern. Med. 166 (1): 49–56. doi:10.1001/archinte.166.1.49. PMID 16401810. Arhivirano iz prvotnega spletišča dne 15. decembra 2019. Pridobljeno 15. oktobra 2011.

amebis.si

lsm1.amebis.si

http://lsm1.amebis.si/lsmeds/novPogoj.aspx?pPogoj=emtricitabin^{[mrtva povezava]}, Slovenski medicinski e-slovar, vpogled 15. 10. 2011.

doi.org

Lim SG; Ng TM; Kung N; in sod. (2006). »A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B«. Arch. Intern. Med. 166 (1): 49–56. doi:10.1001/archinte.166.1.49. PMID 16401810. Arhivirano iz prvotnega spletišča dne 15. decembra 2019. Pridobljeno 15. oktobra 2011.
Oxenius A; Price DA; Günthard HF; in sod. (2002). »Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection«. Proc. Natl. Acad. Sci. U.S.A. 99 (21): 13747–13752. doi:10.1073/pnas.202372199. PMC 129766. PMID 12370434.
Liu KZ; Hou W; Zumbika E; Ni Q (2005). »Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy«. J Zhejiang Univ Sci B. 6 (12): 1182–1187. doi:10.1631/jzus.2005.B1182. PMC 1390641. PMID 16358376. Arhivirano iz prvotnega spletišča dne 10. januarja 2017. Pridobljeno 15. oktobra 2011.

nih.gov

pubmed.ncbi.nlm.nih.gov

Lim SG; Ng TM; Kung N; in sod. (2006). »A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B«. Arch. Intern. Med. 166 (1): 49–56. doi:10.1001/archinte.166.1.49. PMID 16401810. Arhivirano iz prvotnega spletišča dne 15. decembra 2019. Pridobljeno 15. oktobra 2011.
Oxenius A; Price DA; Günthard HF; in sod. (2002). »Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection«. Proc. Natl. Acad. Sci. U.S.A. 99 (21): 13747–13752. doi:10.1073/pnas.202372199. PMC 129766. PMID 12370434.
Liu KZ; Hou W; Zumbika E; Ni Q (2005). »Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy«. J Zhejiang Univ Sci B. 6 (12): 1182–1187. doi:10.1631/jzus.2005.B1182. PMC 1390641. PMID 16358376. Arhivirano iz prvotnega spletišča dne 10. januarja 2017. Pridobljeno 15. oktobra 2011.

ncbi.nlm.nih.gov

Oxenius A; Price DA; Günthard HF; in sod. (2002). »Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection«. Proc. Natl. Acad. Sci. U.S.A. 99 (21): 13747–13752. doi:10.1073/pnas.202372199. PMC 129766. PMID 12370434.
Liu KZ; Hou W; Zumbika E; Ni Q (2005). »Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy«. J Zhejiang Univ Sci B. 6 (12): 1182–1187. doi:10.1631/jzus.2005.B1182. PMC 1390641. PMID 16358376. Arhivirano iz prvotnega spletišča dne 10. januarja 2017. Pridobljeno 15. oktobra 2011.

pnas.org

Oxenius A; Price DA; Günthard HF; in sod. (2002). »Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection«. Proc. Natl. Acad. Sci. U.S.A. 99 (21): 13747–13752. doi:10.1073/pnas.202372199. PMC 129766. PMID 12370434.

web.archive.org

Lim SG; Ng TM; Kung N; in sod. (2006). »A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B«. Arch. Intern. Med. 166 (1): 49–56. doi:10.1001/archinte.166.1.49. PMID 16401810. Arhivirano iz prvotnega spletišča dne 15. decembra 2019. Pridobljeno 15. oktobra 2011.
Liu KZ; Hou W; Zumbika E; Ni Q (2005). »Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy«. J Zhejiang Univ Sci B. 6 (12): 1182–1187. doi:10.1631/jzus.2005.B1182. PMC 1390641. PMID 16358376. Arhivirano iz prvotnega spletišča dne 10. januarja 2017. Pridobljeno 15. oktobra 2011.

zju.edu.cn

Liu KZ; Hou W; Zumbika E; Ni Q (2005). »Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy«. J Zhejiang Univ Sci B. 6 (12): 1182–1187. doi:10.1631/jzus.2005.B1182. PMC 1390641. PMID 16358376. Arhivirano iz prvotnega spletišča dne 10. januarja 2017. Pridobljeno 15. oktobra 2011.